SynthesisImmunity, inflammation and disease2024
Diagnostic Efficacy of 11 SARS-CoV-2 Serological Assays for COVID-19: A Meta-Analysis and Adjusted Indirect Comparison of Diagnostic Test Accuracy.
Synthesis in Immunity, inflammation and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn the past 5 years, a large number of serological assays for large-scale detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen emerged. Serological assays for SARS-CoV-2 were needed to support clinical diagnosis and epidemiological investigations. However, there were limited data on the diagnostic accuracy of these serological assays. We aimed to compare the diagnostic accuracy of 11 commercial serological assays for coronavirus disease-2019 (COVID-19) by taking the reverse transcriptase polymerase chain reaction (RT-PCR) assays as the reference standard, which served as the control arm to conduct an indirect comparison of diagnostic accuracy for 11 different SARS-CoV-2 serological assays.
methodsThis meta-analysis was conducted following the PRISMA 2020 reporting guideline. Electronic searches were performed using the Cochrane Library, PubMed, Embase, Web of Science, Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI), WANFANG, and Chinese Weipu (VIP) databases. Fifty-seven articles, including 11 serologic-based IgG, IgM, and total antibodies assays for SARS-CoV-2, published before June 2024, were included in this meta-analysis. The main outcome of this meta-analysis used to evaluate the performance of 11 assays included pooled diagnostic odds ratio (DOR), area under the summary receiver operating characteristic (AUC), and summary receiver operating characteristic curve (SROC). The R software was used for adjusted indirect comparison to calculate the relative diagnostic odds ratio (RDOR) with corresponding 95% confidence intervals (CIs), and indirect comparison forest plots showed the results.
resultsA total of 57 articles met the eligibility criteria for inclusion in our meta-analysis. The pooled DOR and the AUC for access SARS-CoV-2 IgG were 564.28 (95% CI 229.58-1386.91) and 1.00, and as for EDI novel coronavirus COVID-19 IgG those were 85.27 (95% CI 53.99-134.68) and 0.95, for EDI novel coronavirus COVID-19 IgM were 49.42 (95% CI 16.47-148.30) and 0.86, for iFlash-SARS-CoV-2 IgG were 652.31 (95% CI 362.32-1174.41) and 0.97, for iFlash-SARS-CoV-2 IgM were 36.72 (95% CI 12.42-108.54) and 0.76, for MAGLUMI 2019-nCoV IgG were 145.44 (95% CI 59.37-356.30) and 0.90, for MAGLUMI 2019-nCoV IgM were 21.59 (95% CI 14.27-32.67) and 0.59, for ortho-clinical anti-SARS-CoV-2 IgG were 719.46 (95% CI 262.34-1973.13) and 1.00, for ortho-clinical anti-SARS-CoV-2 total were 1104.60 (95% CI 395.64-3083.99) and 1.00, for Siemens SARS-CoV-2 total (COV2T) were 1143.37 (95% CI 316.49-4130.62) and 0.99, for Wantai SARS-CoV-2 total Ab were 1014.98 (95% CI 618.48-1665.66) and 1.00. The pooled DOR for assays-based IgG (n = 43), assays-based total antibody (n = 35), and assays-based IgM (n = 20) was 242.88 (95% CI 157.66-374.16), 1215.90 (95% CI 547.14-2702.07), and 40.99 (95% CI 22.63-74.25). The diagnostic accuracy of assays-based total antibody performed better than those of assays-based IgG and assays-based IgM; assays-based IgG performed better than assays-based IgM.
conclusionThis study suggested that the Siemens SARS-CoV-2 total (COV2T), ortho-clinical anti-SARS-CoV-2 total, and Wantai SARS-CoV-2 total had the best overall diagnostic accuracy. The diagnostic efficacy of the assays-based total antibody had statistically significantly higher accuracy than those of assays-based IgG and assays-based IgM for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.